title: Decreased circulating levels of oxytocin in obesity and newly diagnosed type 2 diabetic patients.
abstract: OBJECTIVE
  Oxytocin can affect energy homeostasis and has interesting potential as a metabolic disease therapeutic. We detected serum oxytocin levels in obese (OB) and type 2 diabetes mellitus (T2DM) subjects and investigated the relationships between serum oxytocin levels and glycolipid metabolism, insulin resistance, pancreatic β-cell function, and inflammation.
  
  
  METHODS
  A total of 176 subjects were enrolled in the study, including 88 patients with newly diagnosed T2DM and 88 subjects with normal glucose tolerance (NGT). NGT and T2DM groups were divided into normal-weight (NW) and OB subgroups. We analyzed the concentrations of oxytocin by ELISA. Oral glucose tolerance testing was done, and hemoglobin A1c (HbA1c), blood lipids, and highly sensitive C-reactive protein (hs-CRP) were also measured. Insulin resistance and pancreatic β-cell function were assessed by homeostasis model assessment (HOMA).
  
  
  RESULTS
  Serum oxytocin levels were lower in the T2DM group than in the NGT group (P < .01). The levels of serum oxytocin in OB subjects were also lower than those in NW subjects (P < .01). Serum oxytocin levels were negatively correlated with body mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR), HbA1c, fasting plasma glucose (FPG), 2-hour plasma glucose, fasting insulin (FINS), 2-h insulin, total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), HOMA of insulin resistance (HOMA-IR), and hs-CRP and positively correlated with HOMA of β-cell function (HOMA-β) (P < .05). Multiple stepwise regression analysis showed that 2-hour plasma glucose, BMI, and TC were associated with serum oxytocin levels (P < .05). Logistic regression analyses demonstrated that serum oxytocin was significantly associated with T2DM (P < .01).
  
  
  CONCLUSIONS
  Serum oxytocin levels were decreased in T2DM as well as OB subjects.
authors.affiliation: Department of Endocrinology (W.Q., T.Z., B.T., S.Y., H.H., W.S., R.P., J.W., D.W., L.Y., C.M., G.Y.), Affiliated Hospital of Jiangsu University, Jiangsu 212001, China; and Ruijin Hospital (L.Z.), Shanghai Institute of Endocrine and Metabolic Diseases, State Key Laboratory of Medical Genomics, Shanghai Jiaotong University Medical School, Shanghai 200025, China.
authors.forename: Weiyun
authors.initials: W
authors.lastname: Qian
authors.forename: Tianyi
authors.initials: T
authors.lastname: Zhu
authors.forename: Bingqian
authors.initials: B
authors.lastname: Tang
authors.forename: Shuqin
authors.initials: S
authors.lastname: Yu
authors.forename: Hao
authors.initials: H
authors.lastname: Hu
authors.forename: Wenjun
authors.initials: W
authors.lastname: Sun
authors.forename: Ruirong
authors.initials: R
authors.lastname: Pan
authors.forename: Jifang
authors.initials: J
authors.lastname: Wang
authors.forename: Dong
authors.initials: D
authors.lastname: Wang
authors.forename: Ling
authors.initials: L
authors.lastname: Yang
authors.forename: Chaoming
authors.initials: C
authors.lastname: Mao
authors.forename: Libin
authors.initials: L
authors.lastname: Zhou
authors.forename: Guoyue
authors.initials: G
authors.lastname: Yuan
mesh_terms: D050154:Adiposity; D000328:Adult; D000368:Aged; D002097:C-Reactive Protein / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006017:Glycolipids / Q000378:metabolism; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology; D050417:Insulin-Secreting Cells / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood*; D010121:Oxytocin / Q000097:blood*; D010186:Pancreatic Function Tests
chemical_list: D002097:C-Reactive Protein; D006442:Glycated Hemoglobin; D006017:Glycolipids; D010121:Oxytocin